首頁 > 市場調查報告書 > 製藥

糖尿病

市場調查報告書

商品編碼

1898151

糖尿病腎臟病市場規模、佔有率和成長分析（按藥物類別、類型、給藥途徑、最終用戶、分銷管道和地區分類）—產業預測（2026-2033 年）

Diabetic Nephropathy Market Size, Share, and Growth Analysis, By Drug Class (Diuretics, Antioxidant Inflammation Modulator), By Type, By Route of Administration, By End-Users, By Distribution Channel, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月17日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，全球糖尿病腎臟病市場規模將達到 24.4 億美元，到 2025 年將達到 25.9 億美元，到 2033 年將達到 41.2 億美元，在預測期（2026-2033 年）內複合年成長率為 6%。

全球糖尿病腎臟病市場持續強勁成長，主要驅動力是糖尿病盛行率的上升以及對有效治療方案日益成長的需求。全球數百萬糖尿病患者，糖尿病腎臟病變高危險群數量龐大，因此亟需創新治療方法。患者數量的快速成長推動了研發工作，尤其是在新型診斷工具和治療策略的開發方面。早期檢測和風險評估方法的進步，包括生物標記和基因檢測，使得及時介入成為可能。此外，新興的標靶療法，例如腎素-血管收縮素-醛固酮系統（RAAS）抑制劑和鈉-葡萄糖共同輸送體2（SGLT2）標靶治療，在控制糖尿病腎臟病變進展方面展現出良好的療效，顯著促進了市場成長。

全球糖尿病腎臟病市場促進因素

醫療保健支出不斷成長，尤其是在開發中國家，是糖尿病腎臟病市場成長的關鍵因素。財政資源的增加使糖尿病腎臟病腎臟病治療方法和支持系統的認知和需求。醫療保健可近性的整體改善是推動該市場擴張的主要因素。

限制全球糖尿病腎臟病市場發展的因素

全球糖尿病腎臟病市場的主要限制因素之一是先進治療方法和藥物的高成本。許多旨在治療糖尿病腎臟病的創新治療方法和尖端技術往往價格昂貴，這會限制患者獲得治療的機會以及對治療方案的依從性。在醫療基礎設施和保險覆蓋不足的地區，這種經濟障礙更為嚴重，導致治療差異。此外，醫療資源匱乏的地區可能缺乏疾病認知和診斷資源，阻礙早期發現和治療，進而影響市場成長和整體治療模式。

全球糖尿病腎臟病市場趨勢

由於糖尿病及其併發症的盛行率不斷上升，以及人口老化，全球糖尿病腎臟病市場呈現顯著的成長趨勢。開發創新有效的治療方法已成為關注的焦點，尤其是在個人化醫療模式日益強調根據個別患者需求量身定做治療方案的背景下。此外，生物技術和藥理學的進步正在提高現有治療方法的療效，而新興生物製藥公司也蓄勢待發，並有望提供新的解決方案。這種充滿活力的市場格局預計將推動市場顯著成長，最終改善患者預後，並重新定義糖尿病腎臟病的治療標準。

禮來公司（美國）
阿斯特捷利康（英國）
強生公司（美國）
諾華公司（瑞士）
拜耳股份公司（德國）
賽諾菲（法國）
默克公司（美國）
第一三共株式會社（日本）
武田藥品工業株式會社（日本）
輝瑞公司（美國）
百時美施貴寶公司（美國）
勃林格殷格翰（德國）
葛蘭素史克有限公司（英國）
艾伯維公司（美國）
Vertex Pharmaceuticals（美國）
安進（美國）
吉利德科學公司（美國）
百健（美國）
再生元製藥公司（美國）

結論與建議

簡介目錄

Product Code: SQMIG35D2095

Global Diabetic Nephropathy Market size was valued at USD 2.44 Billion in 2024 and is poised to grow from USD 2.59 Billion in 2025 to USD 4.12 Billion by 2033, growing at a CAGR of 6% during the forecast period (2026-2033).

The global diabetic nephropathy market is witnessing robust expansion, primarily fueled by the rising prevalence of diabetes and an escalating demand for effective treatment solutions. With millions worldwide impacted by diabetes, there exists a substantial patient base at risk for diabetic nephropathy, intensifying the need for innovative therapeutic options. This surge in patient population is motivating advancements in medical research and technology, particularly in the development of novel diagnostic tools and treatment strategies. Enhanced methods for early detection and risk assessment, including biomarkers and genetic testing, facilitate timely intervention. Furthermore, emerging targeted therapies such as renin-angiotensin-aldosterone system (RAAS) inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors demonstrate promising efficacy in managing the progression of diabetic nephropathy, thereby contributing positively to market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Diabetic Nephropathy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Diabetic Nephropathy Market Segments Analysis

Global Diabetic Nephropathy Market is segmented by Drug Class, Type, Route of Administration, End-Users, Distribution Channel and region. Based on Drug Class, the market is segmented into Diuretics, Antioxidant Inflammation Modulator, Angiotensin Receptor Blockers, Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors), Renin Inhibitors, Calcium Channel Blockers and Others. Based on Type, the market is segmented into Type-1 Diabetes and Type-2 Diabetes. Based on Route of Administration, the market is segmented into Oral, Parental and Others. Based on End-Users, the market is segmented into Hospitals, Homecare, Specialty Centers and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Online Pharmacy and Retail Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Diabetic Nephropathy Market

The rising healthcare spending, especially in developing nations, plays a crucial role in the growth of the diabetic nephropathy market. This boost in financial resources allows for improved access to healthcare services, diagnostic tools, medications, and comprehensive treatment alternatives for those affected by diabetic nephropathy. As healthcare infrastructure becomes more robust due to enhanced funding, patients benefit from better management of their condition, leading to increased awareness and demand for effective therapies and support systems targeted at diabetic nephropathy. This overall improvement in healthcare accessibility is a key driver for the expansion of this market.

Restraints in the Global Diabetic Nephropathy Market

One key market restraint for the global diabetic nephropathy market is the high cost of advanced treatment options and medications. Many breakthrough therapies and cutting-edge technologies aimed at managing diabetic nephropathy tend to be prohibitively expensive, which can limit patient access and adherence to treatment regimens. This financial barrier is further exacerbated in regions with less robust healthcare infrastructure and insurance coverage, leading to disparities in treatment availability. Additionally, there may be a lack of awareness and diagnostic resources in underserved areas, hindering early detection and management of the disease, consequently affecting market growth and the overall therapeutic landscape.

Market Trends of the Global Diabetic Nephropathy Market

The Global Diabetic Nephropathy market is experiencing a significant uptrend driven by the increasing prevalence of diabetes and its associated complications, further exacerbated by an aging population. The focus on developing innovative and effective treatments is prominent, particularly with a shift towards personalized medicine, which aims to tailor therapies to individual patient needs. Additionally, advancements in biotechnology and pharmacology are enhancing the efficacy of existing therapies, while emerging biopharmaceuticals are poised to offer novel solutions. This dynamic landscape is expected to drive substantial growth in the market, ultimately improving patient outcomes and redefining standard care practices for diabetic nephropathy.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Diabetic Nephropathy Market Size by Drug Class & CAGR (2026-2033)

Market Overview
Diuretics
Antioxidant Inflammation Modulator
Angiotensin Receptor Blockers
Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
Renin Inhibitors
Calcium Channel Blockers
Others

Global Diabetic Nephropathy Market Size by Type & CAGR (2026-2033)

Market Overview
Type-1 Diabetes
Type-2 Diabetes

Global Diabetic Nephropathy Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Oral
Parental
Others

Global Diabetic Nephropathy Market Size by End-Users & CAGR (2026-2033)

Market Overview
Hospitals
Homecare
Specialty Centers
Others

Global Diabetic Nephropathy Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy

Global Diabetic Nephropathy Market Size & CAGR (2026-2033)

North America (Drug Class, Type, Route of Administration, End-Users, Distribution Channel)
- US
- Canada
Europe (Drug Class, Type, Route of Administration, End-Users, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Drug Class, Type, Route of Administration, End-Users, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Drug Class, Type, Route of Administration, End-Users, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Drug Class, Type, Route of Administration, End-Users, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Daiichi Sankyo Company, Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vertex Pharmaceuticals (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments